Apararenone 是一种新型的、非甾体类盐皮质激素受体 (mineralocorticoid receptor) 拮抗剂，正在开发用于糖尿病性肾病和非酒精性脂肪性肝炎的研究。

Apararenone is a receptor antagonist of mineralocorticoid receptor which can be used to treat non-alcoholic steatohepatitis and diabetic nephropathy.

A phase II clinical trial has been initiated among patients with non-alcoholic steatohepatitis (NASH) in Japan[1].

945966-46-1

C17H17FN2O4S

364.39

MT-3995

DMSO:125 mg/mL (343.04 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years